Selleckchem.com

Compound Libraries



1 Selleck Compound Libraries have been cited in over 1,465 studies!

- Int J Mol Sci,2024,25(2)1265
- Cell Rep Med,2024,S2666-3791(23)00604-3
- J Med Virol,2024,96(1):e29382
- Int Immunopharmacol,2024,128:111570
- Front Oncol,2023,13:1126354
- Microbiol Spectr,2023,11(4):e0056623
- Microbiol Spectr,2023,11(4):e0056623
- Pharmaceuticals (Basel),2023,16(1)75
- J Biol Chem,2023,S0021-9258(23)01885-9
- Breast Cancer Res,2023,25(1):51
- Biomolecules,2023,13(2)249
- J Exp Clin Cancer Res,2023,42(1):100
- Stem Cell Reports,2023,18(8):1672-1685
- Biomedicines,2023,11(6)1716
- Cell Div,2023,18(1):8
- Cancer Lett,2023,552:215981
- Adv Sci (Weinh),2023,10(5):e2205483
- Aging Cell,2023,22(10):e13948
- Stem Cell Reports,2023,18(8):1672-1685
- Sci Rep,2023,13(1):1442
- Biomedicines,2023,11(6)1716
- Sci Adv,2023,9(1):eade1694
- Eur J Pharm Sci,2023,181:106362
- Front Microbiol,2023,14:1097413
- ACS Omega,2023,8(11):10397-10402
- Exp Mol Med,2023,55(4):794-805
- Cancers (Basel),2023,15(7)2163
- Front Cardiovasc Med,2023,10:1130635
- Am J Cancer Res,2023,13(3):976-991
- Int J Biol Sci,2023,19(7):2270-2288
- Adv Healthc Mater,2023,e2300591.
- Int J Mol Sci,2023,24(8)7578
- Bioorg Chem,2023,130:106264
- Int J Mol Sci,2023,24(7)6038
- Sci Adv,2023,10.1126/sciadv.adf0005
- ERJ Open Res,2023,9(1)00495-2022
- Pharmaceutics,2023,15(3)925
- Acta Pharm Sin B,2023,13(1):142-156
- Chin Med,2023,18(1):30
- Sci Rep,2023,13(1):14429
- mBio,2023,e0137623.
- Front Pharmacol,2023,14:1233253
- Chembiochem,2023,e202300555.
- J Exp Clin Cancer Res,2023,42(1):249
- Nat Commun,2023,14(1):6690
- Nat Commun,2023,14(1):7574
- Sci Rep,2023,13(1):19588
- Virus Res,2023,339:199248
- ASN Neuro,2023,
- Int J Mol Sci,2023,24(13)10696
- ASN Neuro,2023,15:17590914231184086
- J Biol Chem,2023,299(3):102956
- J Exp Clin Cancer Res,2023,42(1):249
- Nat Prod Commun,2023,18(1)
- Cancer Res Commun,2023,3(7):1152-1165
- mBio,2023,14(4):e0137623
- Nat Commun,2023,14(1):6690
- ERJ Open Res,2023,9(1)00495-2022
- Cell Death Discov,2023,9(1):57
- Chin Med,2023,18(1):30
- ...

Number of Publications Citing Selleck Compound Libraries (2013-2023)



2 High hit rates, rapid screening, and high-impact publications.

Based on published data, for every **100 Selleck compounds** used in primary screening, an average of **five target-active compounds** can be identified. The probability of obtaining target-active compounds generally increases with the number of compounds screened.

The following are examples of research papers that used Selleck Compound Libraries for screening:

Journal	IF	Time from Purchase to Publication	Total Number of Compounds in the Library	Number of Hit Compounds Identified	Selleck Compound Library
Cancer Cell	35.5	~13 months	~1,000	25	Customize Library (L2000)
Journal of the American Chemical Society	15.8	~10 months	3,725	488	Customize Library (L2000)
Nature Chemical Biology	15.7	~17 months	1,833	19	Customize Library (L2000)
Nature Communications	12.1	~14 months	74	14	Customize Library (L2000)
Viruses	3.8	~14 months	179	42	Customize Library (L2000)
Biomaterials	12.1	~12 months	1,226	15	FDA-approved Drug Library (L1300)
Cancer Letters	8.6	~12 months	1,431	12	FDA-approved Drug Library (L1300)
Protein & Cell	11.3	~12 months	3,035	12	FDA-approved Drug Library (L1300)
Protein & Cell	11.3	~21 months	2,661	12	Natural Product Library (L1400)
Nature Communications	12.1	~24 months	138	4	Natural Product Library (L1400)
Journal of Biomolecular Structure and Dynamics	2.7	~18 months	2,820	20	FDA-approved & Passed Phase I Drug Library (L3800)
Antiviral Research	5.8	~17 months	12,000	23	FDA-approved Drug Library (L1300)
Antiviral Research	5.8	~14 months	12,000	23	Preclinical/Clinical Compound Library (L3900)
Cell Stem Cell	26.3	~15 months	1,753	1,484	Bioactive Compound Library-I (L1700)
Cell Reports	10.4	~12 months	1,836	15	Bioactive Compound Library-I (L1700)
Journal of Biological Chemistry	5	~20 months	12,433	178	Bioactive Compound Library-I (L1700)
Journal of Biological Chemistry	5	~18 months	12,433	178	Bioactive Compound Library-Ⅱ (L1700-Ⅱ)
elife	9	~13 months	6,500	167	Kinase Inhibitor Library (L1200)
Journal of Biomolecular Structure and Dynamics	2.7	~20 months	4,208	1,230	Express-Pick Library (L3600)
Cell Reports	10.4	~15 months	351	44	Highly Selective Inhibitor Library (L3500)
Journal of Infection and Chemotherapy	2.1	~24 months	584	42	Metabolism Compound Library (L3700)

3 The Nature Medicine article validates the superior quality of Selleck products.

Nature Medicine Reported: 30% of Inhibitors on The Market Fail Basic Standards

Broad Institute recently tested compound libraries from all major producers, their findings show that 30% of all inhibitors don't meet basic standards.

nature medicine

CORRESPONDENCE

The Drug Repurposing Hub: a next-generation drug library and information resource

Data Summary

Supplier Comparison of Products with 0% Purity



Supplier Comparison of Products with >90% Purity



Data From: Nature Medicine, 2017, 23(4):405-408 (IF: 53.440) & The website created by the article author.

4 Popular Compound Libraries

FDA-approved Drug Library

Cat.No. L1300

A unique collection of **3,110** raw materials that have obtained market approval and are included in pharmacopoeias. These drugs have undergone extensive clinical trials, demonstrating good biological activity, safety, and bioavailability. They are suitable for high-throughput and high-content screening.

% of compounds compliant with Lipinski's Rules

Selleck

PhysChem Properties	% Compounds
The number of hydrogen bond donors	93
The number of hydrogen bond acceptors	97
Partition coefficient	91
Molecular weight	75

VS

Other Company

PhysChem Properties	% Compounds
The number of hydrogen bond donors	88
The number of hydrogen bond acceptors	90
Partition coefficient	90
Molecular weight	79

Approved agencies for molecules in the Selleck FDA library

Approved institution	Full name	Country
FDA	U.S. Food and Drug Administration	United States of America
CFDA	China Food and Drug Administration	China
EMA	European Medicines Agency	European
HMA	Heads Of Medicines Agency	European
NDC	National Drug Code	United States of America
PMDA	Pharmaceuticals and Medical Devices Agency	Japan
DMF	Drug Master File	United States of America

FDA-approved Drug Library Composition



Application of FDA-approved Drug Library in Antiviral

Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus (SFTSV) related fatality

This article (PMID:31444469) was published on *Journal of Cell Research* (IF=17) and took about thirteen months.

Summary

Severe fever with thrombocytopenia syndrome (SFTS) is caused by a novel phlebovirus (SFTSV), and there is no effective anti-SFTSV intervention at the present time. The author screened **700** drugs (**Selleck FDA-approved Drug Library**), and finds that calcium channel blockers(**benidipine hydrochloride, nifedipine**) can significantly inhibit SFTSV infection.

Experiment Design

1. Establish Cell Model for Screening

1. Vero cells infected with SFTSV;
2. Using automated imaging and quantitative analysis to test the percentage of SFTSV-infected cells;
3. The cell activity was measured by MTT assay.

2. High-throughput Drug Screening



Compound Library: Selleck FDA-approved Drug Library

Model: Vero cells infected with SFTSV

Indicators: Virus infection (inhibition rate) and cell cytotoxicity (survive rate)

Results: Seven drugs displayed anti-SFTSV activity in a dose-dependent manner, and benidipine hydrochloride displayed the strongest inhibitory effect.

3. Mechanism Research



Benidipine hydrochloride can significantly reduce the intracellular vRNA level of SFTSV

A retrospective clinical investigation on 2087 SFTS patients showed that nifedipine can distinctly inhibit SFTSV infection and reduce SFTS-associated CFR

Natural Product Library

Cat.No. L1400

Natural products are small molecules extracted from animals, plants, and microorganisms in nature, known for their rich and complex chemical structures and biological activities. Many drugs used in clinical practice are derived from natural sources, constituting about 60% of modern pharmaceuticals. Research on natural products is crucial for lead compound discovery, traditional Chinese medicine development, and the advancement of applied chemistry.

The **Selleck Natural Product Library** comprises **3,070** compounds and derivatives sourced from diverse origins. With a wide range of structures and targeting multiple signaling pathways, these compounds are ideal for high-throughput screening. The Selleck Natural Product Library is sourced from the following:



Cited by 383 Publications:

- Nat Methods, 2022 19(7):803-811
- Signal Transduct Target Ther, 2022 7(1):97
- Nat Biomed Eng, 2022 10.1038/s41551-022-00863-9
- Blood, 2022 blood.2022015414
- Cancer Cell, 2021 S1535-6108(21)00383-4
- Chem Soc Rev, 2021 10.1039/d0cs01065k
- Cancer Discov, 2021 candisc.0872.2020
- Cancer Discov, 2021 candisc.0930.2020
- Protein Cell, 2021 1-12
- Nature, 2020 582(7811):289-293
- Cell, 2020 181(7):1518-1532.e14
- Signal Transduct Target Ther, 2020 4;5:20.
- Cell Metab, 2019 7;29(5):1166-1181.e6.
- Cancer Discov, 2019 9(7):910-925
- Protein Cell, 2019 10(6):417-435
- Cancer Discov, 2018 8(4):498-515
- Nature, 2017 546(7659):533-538
- Cancer Discov, 2015 5(2):154-67.
- Nat Med, 2014 20(8):954-60
- Comput Biol Med, 2024 171:108163
- Nat Commun, 2023 14(1):7574
- Adv Sci (Weinh), 2023 10(13):e2206737
- Sci Data, 2023 10(1):296
- J Transl Med, 2023 21(1):553
- Anal Chem, 2023 95(20):7985-7992.
- Cell Death Discov, 2023 9(1):364
- J Infect Dis, 2023 228(5):591-603
- Nutrients, 2023 15(6)1490
- Int J Mol Sci, 2023 24(19)14479
- Int J Mol Sci, 2023 24(18)14271
- Pharmaceutics, 2023 15(2)675
- ...

HTS Library for Drug Discovery

Cat.No. L5000

A unique collection of **99,039** compounds, involving over **4,000** core structures, with enhanced structural complexity; compounds have molecular weights ranging from 300 to 500, exhibiting strong drug-like properties, good drugability, and ease of identifying active molecules; sourced from Pfizer, the world's largest pharmaceutical company, with over fifty years of research and development expertise. Suitable for high-throughput screening and high-content screening.

- **Enhanced structural complexity:** Contains **99,039** compounds, involving over **4,000** core structures, suitable for high-throughput screening and high-content screening.
- **Strong drug-like properties:** Compounds with molecular weights ranging from 300 to 500 exhibit strong drug-like properties, good drugability, and ease of identifying active molecules, improving the efficiency of drug discovery.
- Sourced from Pfizer, the world's largest pharmaceutical company, with over fifty years of research and development expertise.

% of compounds compliant with Lipinski's Rules

PhysChem Properties	% Compounds
The number of hydrogen bond donors	94
The number of hydrogen bond acceptors	97
Partition coefficient	95
Molecular weight	100

Molecular weight of all compounds < 500 !

- Good oral absorption
- Good membrane permeability
- Good metabolic stability Simple structure
- Easy to synthesize and optimize

Customize Library

Cat.No. L2000

No suitable compound library? The exclusive compound library can be customized according to your needs.

You could select:

Specific Compounds

Quantity

96 or 384 well Plate

Dry/solid or DMSO solution

Please contact us at info@selleckchem.com to customize your library.

5 Applicable Screening Methods

Selleck Compound Library is suitable for phenotypic assays (cell morphology, cell viability, animal phenotypes), fluorescence-based assays (luciferase reporter genes, fluorescent labeling), and ligand binding assays (SPR).

Phenotypic Assay (Cell Morphology)

Cell seeding and overnight incubation ➡ Treatment with diluted library compounds ➡ Observation of cell morphology

high-content imaging



Fluorescence-based Assay (Luciferase Reporter Gene)

Plasmid construction and co-transfection ➡ Treatment with diluted library compounds ➡ Addition of luciferase substrate and fluorescence detection



6 Selleck Compound Libraries

Popular Compound Libraries(14)

HOT

FDA-approved Drug Library

Cat.No. L1300

- A unique collection of **3,110** approved drugs and API included in pharmacopoeia for high throughput screening (HTS) and high content screening (HCS)
- Verified biological activity and safety profile
- Suitable for drug repurposing
- Includes approved drug information and clinical trial data

Cited by 585 Publications

Nat Methods, 2022 19(7):803-811
Nat Biomed Eng, 2022 10.1038/s41551...
Blood, 2022 blood.2022015414
Cancer Cell, 2021 S1535-6108(21)00383-4
Chem Soc Rev, 2021 10.1039/d0cs01065k
Cancer Discov, 2021 candisc.0872.2020
Cancer Discov, 2021 candisc.0930.2020
Protein Cell, 2021 1-12
Nature, 2020 582(7811):289-293
Cell, 2020 181(7):1518-1532.e14
Cancer Cell, 2020 37(2):200-215.e5
Cell Res, 2020 27;1-16.
Signal Transduct Target Ther, 2020 4;5:20.
Cell Res, 2019 29(9):739-753
Cell Metab, 2019 7;29(5):1166-1181.e6.
Cancer Discov, 2019 9(7):910-925
Protein Cell, 2019 10(3):161-177
Cancer Discov, 2018 8(4):498-515
Nat Med, 2017 23(4):405-408
Nature, 2017 546(7659):533-538
Physiol Rev, 2017 1;97(3):889-938.
Cell Stem Cell, 2017 4;20(5):659-674.e9.
Cancer Discov, 2015 5(2):154-67.
...

FDA-approved & Passed Phase I Drug Library

Cat.No. L3800

- A unique collection of **3,622** drugs that are marketed around the world or have passed clinical phase 1 and can be used for high throughput screening (HTS) and high content screening (HCS)
- Verified biological activity and safety profile
- Suitable for drug repurposing
- Includes approved drug information and clinical trial data

Cited by 288 Publications

Nat Methods, 2022 19(7):803-811
Nat Biomed Eng, 2022 10.1038/s41551...
Blood, 2022 blood.2022015414
Cancer Cell, 2021 S1535-6108(21)00383-4
Chem Soc Rev, 2021 10.1039/d0cs01065k
Cancer Discov, 2021 candisc.0872.2020
Cancer Discov, 2021 candisc.0930.2020
Cell, 2020 181(7):1518-1532.e14
Signal Transduct Target Ther, 2020 4;5:20.
Cell Metab, 2019 7;29(5):1166-1181.e6.
Cancer Discov, 2019 9(7):910-925
Cancer Discov, 2018 8(4):498-515
Nature, 2017 546(7659):533-538
Cancer Discov, 2015 5(2):154-67.
Nat Med, 2014 20(8):954-60
Nat Commun, 2023 14(1):3445
Exp Mol Med, 2023 55(3):612-627
Anal Chem, 2023 95(20):7985-7992.
J Infect Dis, 2023 228(5):591-603
...

Preclinical/Clinical Compound Library

Cat.No. L3900

- A unique collection of **3,368** preclinical and clinical compounds for high throughput screening (HTS) and high content screening (HCS)
- Related to oncology, cardiology, anti-inflammatory, immunology, neuropsychiatry, analgesia etc.
- Verified biological activity and safety profile
- A useful tool for drug repurposing, the application of known drugs to treat new disease indication
- Includes approved drug information and clinical trial data

Cited by 286 Publications

Nat Methods, 2022 19(7):803-811
Nat Biomed Eng, 2022 10.1038/s41551...
Blood, 2022 blood.2022015414
Cancer Cell, 2021 S1535-6108(21)00383-4
Chem Soc Rev, 2021 10.1039/d0cs01065k
Cancer Discov, 2021 candisc.0872.2020
Cancer Discov, 2021 candisc.0930.2020
Cell, 2020 181(7):1518-1532.e14
Signal Transduct Target Ther, 2020 4;5:20.
Cell Metab, 2019 7;29(5):1166-1181.e6.
Cancer Discov, 2019 9(7):910-925
Cancer Discov, 2018 8(4):498-515
Nature, 2017 546(7659):533-538
Cancer Discov, 2015 5(2):154-67.
Nat Med, 2014 20(8):954-60
Nat Commun, 2023 14(1):6951
Anal Chem, 2023 95(20):7985-7992.
J Infect Dis, 2023 228(5):591-603
J Biol Chem, 2023 299(3):102956
bioRxiv, 2023 10.1101/2023.09.15.557919
Br J Cancer, 2022 126(12):1815-1823.
Bioact Mater, 2022 14:272-289
Sci Transl Med, 2022 14(652):eabl5654
...

Bioactive Compound Library-I

Cat.No. L1700

- A unique collection of **9,987** bioactive compounds for high throughput screening (HTS) and high content screening (HCS)
- Large compound collection, ideal for high-throughput screening
- Suitable for researchers without specific research targets to conduct exploratory screening

Cited by 367 Publications

Nat Biotechnol, 2023 10.1038/s41587-023...
Nat Methods, 2022 19(7):803-811
Nat Biomed Eng, 2022 10.1038/s41551...
Blood, 2022 blood.2022015414
Cancer Cell, 2021 S1535-6108(21)00383-4
Chem Soc Rev, 2021 10.1039/d0cs01065k
Cancer Discov, 2021 candisc.0872.2020
Cancer Discov, 2021 candisc.0930.2020
Cell Stem Cell, 2021 28(2):257-272.e11
Nat Metab, 2021 3(5):682-700
Cell, 2020 181(7):1518-1532.e14
Cell Res, 2020 30(8):678-692
Signal Transduct Target Ther, 2020 4;5:20.
Cell Metab, 2020 31(3):564-579
Cell, 2019 7;176(4):687-701.e5.
Cell Metab, 2019 7;29(5):1166-1181.e6.
Cancer Discov, 2019 9(7):910-925
Cancer Discov, 2018 8(4):498-515
Nat Med, 2017 23(4):405-408
Nature, 2017 546(7659):533-538
Physiol Rev, 2017 1;97(3):889-938.
Cancer Cell, 2016 29(6):874-888
Cancer Discov, 2015 5(2):154-67.
Nat Med, 2014 20(8):954-60
Proc Natl Acad Sci U S A, 2023 120(4)...
Haematologica, 2023 108(5):1272-1283
Anal Chem, 2023 95(20):7985-7992.
J Infect Dis, 2023 228(5):591-603
iScience, 2023 26(9):107548
Cancers (Basel), 2023 15(22)5347
Front Mol Biosci, 2023 10:1104505
Sci Rep, 2023 13(1):14911
Pharmaceuticals (Basel), 2023 16(4)548
ACS Omega, 2023 8(11):10397-10402
Mol Pain, 2023 19:17448069221148351
...

Bioactive Compound Library-Ⅱ

Cat.No. L1700-Ⅱ

- A unique collection of **5,309** bioactive compounds for high throughput screening (HTS) and high content screening (HCS)
- Innovative compounds from the largest pharmaceutical company in the world, Diverse and novel bioactivity
- Large compound collection, ideal for high-throughput screening
- Suitable for researchers without specific research targets to conduct exploratory screening

Cited by 19 Publications

Nat Biotechnol, 2023 10.1038/s41587-023...
Proc Natl Acad Sci U S A, 2023 120(4)...
Haematologica, 2023 108(5):1272-1283
iScience, 2023 26(9):107548
Cancers (Basel), 2023 15(22)5347
Front Mol Biosci, 2023 10:1104505
Sci Rep, 2023 13(1):14911
Pharmaceuticals (Basel), 2023 16(4)548
ACS Omega, 2023 8(11):10397-10402
Mol Pain, 2023 19:17448069221148351
Bioinform Biol Insights, 2023 17...
bioRxiv, 2023 2023.07.19.549715
Cancer Res, 2022 82(4):721-733
Proc Natl Acad Sci U S A, 2022 119(11)...
Cell Syst, 2022 13(7):547-560.e3
Cell Calcium, 2022 106:102640
Mol Biol Cell, 2022 33(6):ar54
J Biol Chem, 2021 S0021-9258(21)00703-
...

Kinase Inhibitor Library

Cat.No. L1200

- A unique collection of **2,015** kinase inhibitors for high throughput screening (HTS) and high content screening (HCS)
- Targets kinases such as EGFR, PI3K, Aurora Kinase, CDK, and MEK
- Covers a wide range of kinase targets

Cited by 419 Publications

Nat Methods, 2022 19(7):803-811
Nat Biomed Eng, 2022 10.1038/s41551...
Nat Cell Biol, 2022 24(1):88-98
Blood, 2022 blood.2022015414
Cancer Cell, 2021 S1535-6108(21)00383-4
Chem Soc Rev, 2021 10.1039/d0cs01065k
Cancer Discov, 2021 candisc.0872.2020
Cancer Discov, 2021 candisc.0930.2020
Gut, 2021 70(5):890-899
Cell, 2020 181(7):1518-1532.e14
Nat Methods, 2020 17(3):302-310
Signal Transduct Target Ther, 2020 4;5:20.
Cell Metab, 2019 7;29(5):1166-1181.e6.
Cancer Discov, 2019 9(7):910-925
Cancer Discov, 2018 8(4):498-515
Nat Med, 2017 23(4):405-408
Nature, 2017 546(7659):533-538
Cancer Cell, 2017 32(5):684-700
Gastroenterology, 2017 153(5):1429-1443
Cancer Cell, 2015 28(2):240-52
Cancer Discov, 2015 5(2):154-67.
Nat Med, 2014 20(8):954-60
Nat Commun, 2024 15(1):1041
Adv Sci (Weinh), 2023 10(5):e2205483
Cancer Lett, 2023 552:215981
Aging Cell, 2023 22(10):e13948
Breast Cancer Res, 2023 25(1):51
Anal Chem, 2023 95(20):7985-7992.
J Infect Dis, 2023 228(5):591-603
Stem Cell Reports, 2023 18(8):1672-1685
Biomolecules, 2023 13(2)249
J Biol Chem, 2023 S0021-9258(23)01885-9
Biomedicines, 2023 11(6)1716
Sci Rep, 2023 13(1):1442
Pharmaceuticals (Basel), 2023 16(1)75
Cell Div, 2023 18(1):8
bioRxiv, 2023 10.1101/2023.09.15.557919
Br J Cancer, 2022 126(12):1815-1823.
Sci Transl Med, 2022 14(652):eabl5654
Nat Commun, 2022 13(1):2169
Nat Commun, 2022 13(1):2725
Nat Commun, 2022 13(1):2572
Adv Sci (Weinh), 2022 9(22):e2201785
Nucleic Acids Res, 2022 50(13):7420-7435
J Med Virol, 2022 10.1002/jmv.27951
Cell Death Differ, 2022 10.1038/s41418-022...
Clin Cancer Res, 2022 clincanres.0100.2022
J Exp Clin Cancer Res, 2022 41(1):86
Clin Transl Med, 2022 12(7):e961
Haematologica, 2022 107(1): 77–85
BMC Med, 2022 20(1):175
...

Clinical and FDA-approved Related (4)

FDA-approved Drug Library Cat.No. L1300
A unique collection of 3,110 approved drugs

FDA-approved & Passed Phase I Drug Library Cat.No. L3800
3,622 Compounds

Preclinical/Clinical Compound Library Cat.No. L3900
3,368 Compounds

FDA-approved Anticancer Drug Library Cat.No. L8000
1,746 Compounds

Bioactive Compound Libraries (5)

Bioactive Compound Library-I Cat.No. L1700
9,987 Compounds

Bioactive Compound Library-Ⅱ Cat.No. L1700-Ⅱ
5,309 Compounds

Express-Pick Library Cat.No. L3600
3,010 Compounds

HTS Library for Drug Discovery Cat.No. L5000
99,010 Compounds

Phenotypic Screening Library Cat.No. L8500
4,233 Compounds

Inhibitor Related (7)

Kinase Inhibitor Library Cat.No. L1200
2,015 Compounds

Highly Selective Inhibitor Library Cat.No. L3500
590 Compounds

Cytokine Inhibitor Library Cat.No. L9500
633 Compounds

Inhibitor Library Cat.No. L1100
4,943 Compounds

Protease Inhibitor Library Cat.No. L2500
456 Compounds

Protein-protein Interaction Inhibitor Library Cat.No. L8100
408 Compounds

Tyrosine Kinase Inhibitor Library Cat.No. L1800
654 Compounds

Natural Product and Medicine Food Homology Related (9)

Natural Product Library Cat.No. L1400
3,070 Compounds

Alkaloid Compound Library Cat.No. L7900
441 Compounds

Flavonoid Compound Library Cat.No. L7700
260 Compounds

Medicine Food Homology Compound Library Cat.No. L6800
531 Compounds

Natural Organic Compound Library Cat.No. L7600
1,253 Compounds

Plant Extract Library Cat.No. L9800
796 Compounds

Natural Phenol Compound Library Cat.No. L1410
571 Compounds

Natural Terpenoid Compound Library Cat.No. L1420
356 Compounds

Traditional Chinese Medicine Library Cat.No. L8300
1,913 Compounds

Metabolism Related (9)

Metabolism Compound Library Cat.No. L3700 HOT
3,243 Compounds

Carbohydrate Metabolism Compound Library Cat.No. L9100
572 Compounds

Lipid Metabolism Compound Library Cat.No. L9200
521 Compounds

Mouse Metabolite Compound Library Cat.No. L8900
158 Compounds

Human Endogenous Metabolite Compound Library Cat.No. L4500 HOT
848 Compounds

Glutamine Metabolism Compound Library Cat.No. L6900
479 Compounds

Glycolysis Compound Library Cat.No. L8700
430 Compounds

Gut Microbial Metabolite Library Cat.No. L8400
146 Compounds

Mitochondria-Targeted Compound Library Cat.No. L9900
719 Compounds

Cell Death Related (4)

Apoptosis Compound Library Cat.No. L3300
1,231 Compounds

Autophagy Compound Library Cat.No. L2600
1,026 Compounds

Ferroptosis Compound Library Cat.No. L6400
713 Compounds

Pyroptosis Compound Library Cat.No. L7400
756 Compounds

By Signaling Pathway (26)

Calcium Channel Blocker Library Cat.No. L9000
165 Compounds

Exosome Secretion Related Compound Library Cat.No. L8800
52 Compounds

Human Hormone Related Compound Library Cat.No. L9400
454 Compounds

Oxidative Stress Compound Library Cat.No. L9700
1,437 Compounds

Stem Cell Differentiation Compound Library Cat.No. L9300
295 Compounds

Human Transcription Factor Compound Library Cat.No. L9600
740 Compounds

Angiogenesis Related compound Library Cat.No. L5200
404 Compounds

Antioxidant Compound Library Cat.No. L6500
817 Compounds

Cell Cycle compound library Cat.No. L5100
506 Compounds

Cytoskeletal Signaling Pathway Compound Library Cat.No. L6300
543 Compounds

DNA Damage/DNA Repair compound Library Cat.No. L4600
820 Compounds

Endoplasmic Reticulum Stress Compound Library Cat.No. L8600
175 Compounds

Epigenetics Compound Library Cat.No. L1900
868 Compounds

GPCR Compound Library Cat.No. L2200
1,425 Compounds

By Signaling Pathway (25)

HIF-1 Signaling Pathway Compound Library Cat.No. L6100
443 Compounds

Ion Channel Ligand Library Cat.No. L2700
756 Compounds

MAPK Inhibitor Library Cat.No. L3400
258 Compounds

NF-κB Signaling Compound Library Cat.No. L5500
494 Compounds

Stem Cell Signaling Compound Library Cat.No. L2100
1,003 Compounds

Ubiquitination Compound Library Cat.No. L6000
213 Compounds

Histone modification compound library Cat.No. L4900
337 Compounds

JAK/STAT compound library Cat.No. L5400
191 Compounds

Methylation Compound Library Cat.No. L6600
168 Compounds

PI3K/Akt Inhibitor Library Cat.No. L2800
348 Compounds

TGF-beta/Smad compound library Cat.No. L5600
156 Compounds

By Disease (10)

Anti-Aging Compound Library Cat.No. L6200
2295 Compounds

Anti-cancer Compound Library Cat.No. L3000
4,183 Compounds

Anti-cancer Metabolism Compound Library Cat.No. L5700
317 Compounds

Anti-diabetic Compound Library Cat.No. L2900
147 Compounds

Obesity Compound Library Cat.No. L6700
915 Compounds

Anti-alzheimer Disease Compound Library Cat.No. L5900
638 Compounds

Anti-cancer Compound Library- Ⅱ Cat.No. L7100
901 Compounds

Anti-Cardiovascular Disease Compound Library Cat.No. L7500
694 Compounds

Cambridge Cancer Compound Library Cat.No. L2300
245 Compounds

Small Molecule Immuno-Oncology Compound Library Cat.No. L4800
248 Compounds

Anti-infection and Antiviral Related (6)

Antibiotics compound Library Cat.No. L5300
484 Compounds

Anti-parasitic Compound Library Cat.No. L8200
235 Compounds

Macrocyclic Compound Library Cat.No. L7300
184 Compounds

Anti-infection Compound Library Cat.No. L3100
1,569 Compounds

Antiviral Compound Library Cat.No. L7000
757 Compounds

Nucleoside Analogue Library Cat.No. L7200
230 Compounds

Neuronal and Immunology Related (3)

CNS-Penetrant Compound Library Cat.No. L4700
718 Compounds

Immunology/Inflammation Compound Library Cat.No. L4100
3,369 Compounds

Neuronal Signaling Compound Library Cat.No. L4000
1,750 Compounds

Fragment and Covalent Related (3)

Covalent Inhibitor Library Cat.No. L5800 HOT
843 Compounds

Drug-like Compound Library Cat.No. L7800
2,260 Compounds

Fragment Library Cat.No. L1600
1,015 Compounds

CONTACT US

United States

Tel : (832) 582-8158

E-mail: sales@selleckchem.com

Europe

Tel : +49 221 3798 9904

E-mail: eu.order@selleckchem.com